Results 11 to 20 of about 16,267,247 (278)

Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization. [PDF]

MAbs
The Ginkgo Datapoints Antibody Developability (AbDev) Competition, a blinded benchmark for developability prediction characterized entirely on a single, industrial-scale experimental platform, was conducted from September 8 to November 18, 2025.
van Niekerk L, Moller J, Ritter S, Quintero-Cadena P, Cohen R, Channing G, Chungyuon M, Rand L, Smith A, Bhatt A, Pierre Y, Harris B, Ao X, Grippo L, Schwenk M, Rosenbaum A, Allen O, Asi N, Zhu J, Singh A, Sammi D, Jadhav R, Dušek A, Chandra S, Badea V, Thorsteinson N, Blalock N, Kim J, Turnbull OM, Kulkarni A, Kohar V, Gebremedhin N, Deane CM, Tessier PM, Arsiwala A.   +34 more
europepmc   +3 more sources

Developability Evaluation of Single-Domain Antibody-Chelator Conjugates for Diagnostic Radiotracers. [PDF]

Antibodies (Basel)
Background/Objectives: Developability assessment is a critical step in advancing antibody-based molecules toward clinical application. This evaluation typically begins during clinical candidate selection and continues throughout all modifications of the ...
Kaiser PD, Straß S, Maier S, Herbold E, Traenkle B, Zeck A.   +5 more
europepmc   +2 more sources

Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation. [PDF]

MAbs
Antibody therapeutics are a rapidly growing class of biopharmaceuticals, but concerns regarding potential developability issues persist. While complementarity-determining region (CDR) loops are imperative for antigen specificity and mutations are ...
Spanke VA, Egger-Hoerschinger VJ, Seidler CA, Kroell KB, Wieser V, Imhof-Jung S, Weiche B, Bujotzek A, Georges G, Liedl KR.   +9 more
europepmc   +2 more sources

High concentration formulation developability approaches and considerations

mAbs, 2023
The growing need for biologics to be administered subcutaneously and ocularly, coupled with certain indications requiring high doses, has resulted in an increase in drug substance (DS) and drug product (DP) protein concentrations.
Jonathan Zarzar, Tarik Khan, Maniraj Bhagawati, Benjamin Weiche, Jasmin Sydow-Andersen, Alavattam Sreedhara   +5 more
doaj   +2 more sources

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening

mAbs, 2020
Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term ‘developability’ encompasses the feasibility of molecules to successfully progress from discovery to development via ...
Marc Bailly, Carl Mieczkowski, Veronica Juan, Essam Metwally, Daniela Tomazela, Jeanne Baker, Makiko Uchida, Ester Kofman, Fahimeh Raoufi, Soha Motlagh, Yao Yu, Jihea Park, Smita Raghava, John Welsh, Michael Rauscher, Gopalan Raghunathan, Mark Hsieh, Yi-Ling Chen, Hang Thu Nguyen, Nhung Nguyen, Dan Cipriano, Laurence Fayadat-Dilman   +21 more
doaj   +2 more sources

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

mAbs
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs).
Itzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, Oliver M. Turnbull, Bhargav Patel, Zheng Cao, Jais Rose Bjelke, Susanne Nedergaard Grell, Anja Bennet, Alissa M. Hummer, Matthew I. J. Raybould, Charlotte M. Deane, Thomas Egebjerg, Nikolai Lorenzen, Paolo Arosio   +14 more
doaj   +2 more sources

An accelerated surface-mediated stress assay of antibody instability for developability studies

MAbs, 2020
High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and poor conformational stability ...
Paolo Arosio, Umberto Capasso Palmiero, Nikolai Lorenzen   +2 more
exaly   +3 more sources

Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper. [PDF]

MAbs
The assessment of developability and physical stability of antibody therapeutics is a cornerstone of modern biopharmaceutical discovery, increasingly relying on high-throughput automation to screen candidates to identify the most suitable lead candidate.
Wieser V, Spick C, Forster M, Hanke U, Montan K, Grote M, Weiche B.   +6 more
europepmc   +2 more sources

Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability

Communications Biology, 2023
Designing effective monoclonal antibody (mAb) therapeutics faces a multi-parameter optimization challenge known as “developability”, which reflects an antibody’s ability to progress through development stages based on its physicochemical properties ...
Habib Bashour, Eva Smorodina, Matteo Pariset, Jahn Zhong, Rahmad Akbar, Maria Chernigovskaya, Khang Lê Quý, Igor Snapkow, Puneet Rawat, Konrad Krawczyk, Geir Kjetil Sandve, Jose Gutierrez-Marcos, Daniel Nakhaee-Zadeh Gutierrez, Jan Terje Andersen, Victor Greiff   +14 more
doaj   +2 more sources

Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

mAbs
In vitro assessments for the prediction of pharmacokinetic (PK) behavior of biotherapeutics can help identify corresponding liabilities significantly earlier in the discovery timeline.
Tushar Jain, Bianka Prinz, Alexander Marker, Alexander Michel, Katrin Reichel, Valerie Czepczor, Sylvie Klieber, Wei Sun, Sagar Kathuria, Sevim Oezguer Bruederle, Christian Lange, Lena Wahl, Charles Starr, Alessandro Masiero, Lindsay Avery   +14 more
doaj   +2 more sources